Like-To The Moon - Tiger Brokers Online Investing Community - To The Moon

4
1
Favorite

yteaaron88
2021-07-20

Like

BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum

BioNTech SE is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc'

BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

4

Report

Comment（1）

Top
Latest

happytiga
·2021-07-20
done
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":171169659,"tweetId":"171169659","gmtCreate":1626715558271,"gmtModify":1703763924471,"author":{"id":3586955264029856,"idStr":"3586955264029856","authorId":3586955264029856,"authorIdStr":"3586955264029856","name":"yteaaron88","avatar":"https://static.tigerbbs.com/b5a9adeb4d55b3f87731ddb20a7b5fba","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Like&nbsp;</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/171169659","repostId":1160801924,"repostType":4,"repost":{"id":"1160801924","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1626709874,"share":"https://www.laohu8.com/m/news/1160801924?lang=&edition=full","pubTime":"2021-07-19 23:51","market":"us","language":"en","title":"BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum","url":"https://stock-news.laohu8.com/highlight/detail?id=1160801924","media":"Benzinga","summary":"BioNTech SE is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc'","content":"<p><b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b>&nbsp;is&nbsp;buying a cell therapy R&amp;D platform plus a manufacturing site&nbsp;from&nbsp;<b>Gilead Science Inc's</b>GILD 0.91%Kite subsidiary.</p>\n<p>The deal gives BioNTech Kite's R&amp;D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work and the manufacturing center in Gaithersburg, MD, which supplies the clinical trial product.</p>\n<p>This program builds and further extends BioNTech's leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).</p>\n<p>The acquired Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and complement BioNTech's existing cell therapy manufacturing facility in Germany.</p>\n<p>Financial terms were not disclosed.</p>\n<p>Kite's new manufacturing facility in Frederick, MD, for commercial production of CAR T-cell therapy is not part of the purchase agreement.</p>\n<p><b>Price Action:</b>&nbsp;BNTX shares are up 0.86% at $233.46 during the market session on the last check Monday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-19 23:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b>&nbsp;is&nbsp;buying a cell therapy R&amp;D platform plus a manufacturing site&nbsp;from&nbsp;<b>Gilead Science Inc's</b>GILD 0.91%Kite subsidiary.</p>\n<p>The deal gives BioNTech Kite's R&amp;D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work and the manufacturing center in Gaithersburg, MD, which supplies the clinical trial product.</p>\n<p>This program builds and further extends BioNTech's leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).</p>\n<p>The acquired Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and complement BioNTech's existing cell therapy manufacturing facility in Germany.</p>\n<p>Financial terms were not disclosed.</p>\n<p>Kite's new manufacturing facility in Frederick, MD, for commercial production of CAR T-cell therapy is not part of the purchase agreement.</p>\n<p><b>Price Action:</b>&nbsp;BNTX shares are up 0.86% at $233.46 during the market session on the last check Monday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160801924","content_text":"BioNTech SE is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc'sGILD 0.91%Kite subsidiary.\nThe deal gives BioNTech Kite's R&D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work and the manufacturing center in Gaithersburg, MD, which supplies the clinical trial product.\nThis program builds and further extends BioNTech's leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).\nThe acquired Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and complement BioNTech's existing cell therapy manufacturing facility in Germany.\nFinancial terms were not disclosed.\nKite's new manufacturing facility in Frederick, MD, for commercial production of CAR T-cell therapy is not part of the purchase agreement.\nPrice Action: BNTX shares are up 0.86% at $233.46 during the market session on the last check Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":362,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":5265407,"commentId":"5265407","gmtCreate":1626720094254,"gmtModify":1663231180541,"authorId":3577187273279454,"author":{"id":3577187273279454,"idStr":"3577187273279454","authorId":3577187273279454,"name":"happytiga","avatar":"https://community-static.tradeup.com/news/2ed58962ee498ea8e6ca291401eee03e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":171169659,"objectIdStr":"171169659","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"done","text":"done","html":"done","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}